EMA and EU-HTA Alignment
Building One Evidence Strategy for Regulatory Approval and Joint Clinical Assessment
Europe’s evidence environment has entered a new phase. A medicine can now move through the European Medicines Agency’s regulatory assessment while, in parallel, entering the EU-level Joint Clinical Assessment process. These procedures remain legally and methodologically distinct, but manufacturers must increasingly design development programmes capable of supporting both.
For regulatory, health economics and outcomes research, real-world evidence and market-access teams, the strategic question is no longer simply whether the clinical programme can support marketing authorisation. It is whether the total evidence package can also withstand multiple PICO questions, comparative-effectiveness scrutiny and the requirements of national pricing and reimbursement processes after the EU-level assessment.
EMA evaluates whether a medicine’s benefits outweigh its risks for the proposed indication. EU health technology assessment, by contrast, evaluates the relative clinical effectiveness and safety of a health technology against relevant alternatives. The Joint Clinical Assessment does not make a reimbursement decision or determine a price; national authorities remain responsible for those decisions.
This distinction matters because evidence considered adequate for regulatory approval may not fully answer an HTA question. Regulatory studies can use placebo, standard of care or a comparator accepted for the authorisation strategy. HTA assessors may need comparisons against several treatments used across Member States, in differently defined populations and with outcomes that are particularly relevant to patients, clinicians or payers.
The result is a potential evidence gap at launch: a product may demonstrate efficacy and an acceptable safety profile but still face uncertainty about its relative value in the treatment pathway.
Why PICO strategy has become a development issue
Population, Intervention, Comparator and Outcomes, the PICO framework, defines the scope of the clinical questions addressed in a Joint Clinical Assessment. In a diverse European treatment landscape, a single product may generate multiple PICOs because clinical practice, available comparators and positioning differ between Member States.
PICO planning therefore cannot be left until dossier preparation. It should influence evidence generation early enough to shape trial design, comparator selection, subgroup planning, endpoint strategy and the collection of data needed for indirect comparisons.
Cross-functional teams should ask four questions before pivotal evidence plans are locked:
- Which patient populations and clinically relevant subgroups are likely to be requested?
- Which comparators reflect current practice across the most important European markets?
- Will head-to-head evidence exist, and if not, is the evidence network suitable for an indirect comparison?
- Are the endpoints, follow-up periods and estimands relevant to both regulatory and HTA decision-making?
Real-world evidence can complement clinical trials, but it is not an automatic remedy for an incomplete comparative-evidence strategy. Its value depends on the decision question, the fitness of the data and the credibility of the analytical methods.
Potential applications include describing current treatment pathways, quantifying disease burden, identifying relevant populations, characterising unmet need, contextualising single-arm evidence, constructing external comparator cohorts and examining effectiveness or safety after launch. RWE may also help investigate populations that were underrepresented in clinical trials and support the management of residual uncertainty over time.
EMA’s Data Analysis and Real World Interrogation Network, DARWIN EU, illustrates the growing institutional use of real-world data. The network supports studies on medicine utilisation, safety and effectiveness across European data sources. EMA has also reported RWE activity in areas such as women’s health, where real-world studies can provide information on populations not adequately represented in trials.
However, decision-makers will examine whether the evidence is fit for purpose. Important considerations include:
- Data provenance, completeness and relevance to the target population
- Transparent definitions for exposure, comparators, outcomes and follow-up
- Control of confounding, selection bias, missing information and measurement error
- Pre-specified protocols, analytical traceability and reproducibility
- Data-access governance, patient consent and interoperability across registries
The value of earlier regulatory–HTA dialogue
Under the EU HTA framework, developers can request Joint Scientific Consultations, and EMA supports parallel engagement between regulatory scientific advice and these consultations. This creates an opportunity to identify divergent evidence expectations before they become launch-stage problems.
Early dialogue does not guarantee that one trial will satisfy every decision-maker. It can, however, reveal where the evidence plan needs adaptation for example, an additional comparator, a more relevant endpoint, longer follow-up, a planned indirect comparison or a prospective RWE component.
The practical objective should not be to force regulatory and HTA requirements into a single methodology. It should be to build one integrated evidence architecture in which each study and analysis has a clear role across the product lifecycle.
A practical model for an integrated evidence strategy
A robust European evidence plan should connect five activities:
- Map the decision landscape. Define the regulatory indication, anticipated EU-level HTA scope and priority national access questions.
- Forecast plausible PICOs. Use treatment guidelines, clinical practice, pipeline intelligence and country input to anticipate populations, comparators and outcomes.
- Stress-test the pivotal programme. Identify where the trial programme provides direct evidence and where comparative gaps are likely to remain.
- Design complementary evidence deliberately. Plan indirect comparisons, RWE studies, registries or post-authorisation evidence around defined uncertainties, not around the general availability of data.
- Maintain lifecycle governance. Create a cross-functional process so regulatory, clinical, RWE, HEOR and market-access teams update the evidence plan as scientific advice, JCA scoping and national requirements evolve.
What this means for market access
The EU-level Joint Clinical Assessment is intended to reduce duplication in clinical assessment, but it does not eliminate national evidence interpretation, economic evaluation or reimbursement negotiation. Companies will still need to translate the European clinical assessment into country-specific value narratives, economic models and access strategies.
This makes consistency essential. Assumptions about the target population, treatment pathway, comparator and effect size should be traceable across regulatory submissions, JCA evidence, health-economic modelling and national dossiers. Where assumptions differ, the rationale should be explicit.
The organisations best prepared for this environment will treat regulatory approval, JCA and national access as connected evidence milestones, not as three sequential handovers between separate functions.
The next challenge: turning alignment into practice
EMA and HTA bodies answer different questions, and that separation remains important. Yet their evidence needs increasingly intersect in trial design, endpoint selection, comparative methods, uncertainty management and the use of real-world data.
The central challenge for manufacturers is therefore not to create one universal dossier. It is to develop one coherent evidence strategy that can generate the right analyses for different decision-makers without fragmentation, avoidable duplication or late evidence gaps.
As the first wave of Joint Clinical Assessments develops, the most valuable learning will come from practical experience: which PICOs created the greatest pressure, which evidence gaps could be anticipated, where RWE added credible value and how early dialogue changed development decisions.
The European RWE & Market Access Summit 2026 – JCA & PICO Strategy Edition will bring together leaders from pharmaceutical market access, HEOR, RWE, regulatory affairs, HTA and evidence-generation organisations on 21–22 October 2026 at Inntel Hotels Amsterdam Landmark.
The programme will examine EU-HTA implementation, Joint Clinical Assessment strategy, multi-country PICO alignment, RWE generation, uncertainty management, pricing and reimbursement, and the practical alignment of regulatory and market-access evidence.